At a glance
- Originator GlaxoSmithKline
- Class Osteoporosis therapies
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis
Most Recent Events
- 05 Nov 2002 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
- 18 Apr 2002 Discontinued - Phase-I for Postmenopausal osteoporosis in USA (unspecified route)
- 20 Mar 2001 Phase-I clinical trials for Postmenopausal osteoporosis in USA (Unknown route)